{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0001","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Acknowledgements","content_type":"text","pages":"4","tokens_est":771,"char_count":3081,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0002","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"5-7","tokens_est":891,"char_count":3561,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0003","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"8-9","tokens_est":972,"char_count":3886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0004","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.1. Background","content_type":"text","pages":"9","tokens_est":479,"char_count":1916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0005","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"9-10","tokens_est":815,"char_count":3257,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0006","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations","content_type":"text","pages":"10-11","tokens_est":660,"char_count":2637,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0007","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":973,"char_count":3889,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0008","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.2. Advances in TB diagnostic test development, assessment and WHO recommendations | Box. Consolidated list of recommendations on TB diagnostics","content_type":"box","pages":"11-12","caption":"Box. Consolidated list of recommendations on TB diagnostics","tokens_est":887,"char_count":3548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0009","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.3. Scope of this operational handbook","content_type":"text","pages":"12-13","tokens_est":408,"char_count":1631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0010","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.4. Target audience","content_type":"text","pages":"13-14","tokens_est":182,"char_count":727,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0011","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes","content_type":"text","pages":"14","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0012","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"1. Introduction | 1.5. New in this version: a summary of changes | Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","content_type":"box","pages":"15","caption":"Box. Summary of changes in this WHO operational handbook on tuberculosis. Module 3: diagnosis","tokens_est":656,"char_count":2622,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0013","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"16","tokens_est":357,"char_count":1427,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0014","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | Table 2.1. Classes of TB testing technologies and products included in current guidelines","content_type":"table","pages":"17","caption":"Table 2.1. Classes of TB testing technologies and products included in current guidelines","tokens_est":40,"char_count":558,"has_attachment":true,"attachment_id":"Table 2.1.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0015","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations","content_type":"text","pages":"18-19","tokens_est":733,"char_count":2929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0016","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.1. Conventional tests for the diagnosis of TB","content_type":"table","pages":"21","caption":"Table 2.2. Summary of initial tests for TB diagnosis","tokens_est":77,"char_count":707,"has_attachment":true,"attachment_id":"Table 2.2.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0017","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.1. Conventional tests for the diagnosis of TB","content_type":"text","pages":"20","tokens_est":493,"char_count":1972,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0018","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"22","tokens_est":179,"char_count":715,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0019","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Table 2.3. Definition of the class of LC - aNAATs","content_type":"table","pages":"22","caption":"Table 2.3. Definition of the class of LC - aNAATs","tokens_est":26,"char_count":285,"has_attachment":true,"attachment_id":"Table 2.3.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0020","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs","content_type":"text","pages":"22-23","tokens_est":845,"char_count":3377,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0021","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.1. Low-complexity automated NAATs | Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","content_type":"box","pages":"23","caption":"Box 2.1. WHO recommendations on the use of LC- aNAATs (6)","tokens_est":797,"char_count":3188,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0022","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs","content_type":"text","pages":"24","tokens_est":22,"char_count":85,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0023","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Table 2.4. Definition of the class of MC- aNAATs","content_type":"table","pages":"24","caption":"Table 2.4. Definition of the class of MC- aNAATs","tokens_est":29,"char_count":317,"has_attachment":true,"attachment_id":"Table 2.4.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0024","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs","content_type":"text","pages":"24-25","tokens_est":394,"char_count":1573,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0025","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Box 2.2. WHO recommendation on MC- aNAATs (6)","content_type":"box","pages":"25","caption":"Box 2.2. WHO recommendation on MC- aNAATs (6)","tokens_est":407,"char_count":1627,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0026","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.2. Initial tests for diagnosis of TB with drug resistance detection | 2.2.2. Moderate-complexity automated NAATs | Fig. 2.1. Summary of testing procedures for the Bruker Hain FluoroType MTB and MTBDR","content_type":"figure","pages":"25-26","caption":"Fig. 2.1. Summary of testing procedures for the Bruker Hain FluoroType MTB and MTBDR","tokens_est":61,"char_count":241,"has_attachment":true,"attachment_id":"Fig. 2.1.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 2.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0027","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs","content_type":"text","pages":"27","tokens_est":357,"char_count":1426,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0028","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs | Table 2.5. Definition of the class of LC- mNAATs","content_type":"table","pages":"27","caption":"Table 2.5. Definition of the class of LC- mNAATs","tokens_est":21,"char_count":239,"has_attachment":true,"attachment_id":"Table 2.5.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0029","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.1. Low-complexity manual NAATs | Box 2.3. WHO recommendation on LC- mNAATs (6)","content_type":"box","pages":"27","caption":"Box 2.3. WHO recommendation on LC- mNAATs (6)","tokens_est":346,"char_count":1384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0030","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM","content_type":"text","pages":"27","tokens_est":312,"char_count":1248,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0031","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.3. Initial tests for diagnosis of TB without drug resistance detection | 2.3.2. Urine LF- LAM | Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","content_type":"box","pages":"27","caption":"Box 2.4. WHO recommendations on concurrent use of tests in people living with HIV (5)","tokens_est":650,"char_count":2600,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0032","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance","content_type":"text","pages":"28","tokens_est":131,"char_count":523,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0033","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | Table 2.6. Comparison of follow-on tests for the detection of drug resistance","content_type":"table","pages":"29","caption":"Table 2.6. Comparison of follow-on tests for the detection of drug resistance","tokens_est":68,"char_count":1207,"has_attachment":true,"attachment_id":"Table 2.6.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0034","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"text","pages":"30","tokens_est":246,"char_count":983,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0035","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.1. LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs | Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","content_type":"box","pages":"30-31","caption":"Box 2.5. WHO recommendations on LC- aNAATs for detection of resistance to INH and second-line anti-TB drugs","tokens_est":864,"char_count":3456,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0036","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays","content_type":"text","pages":"31","tokens_est":122,"char_count":488,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0037","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Table 2.7. Definition of the class criteria for LPAs","content_type":"table","pages":"32","caption":"Table 2.7. Definition of the class criteria for LPAs","tokens_est":35,"char_count":138,"has_attachment":true,"attachment_id":"Table 2.7.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.7..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0038","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | First-line drug LPAs","content_type":"text","pages":"32","tokens_est":60,"char_count":237,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0039","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | First-line drug LPAs | Box 2.6. WHO recommendation on FL-LPAs (6)","content_type":"box","pages":"32","caption":"Box 2.6. WHO recommendation on FL-LPAs (6)","tokens_est":361,"char_count":1444,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0040","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Second-line drug LPAs","content_type":"text","pages":"33","tokens_est":38,"char_count":151,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0041","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.2. Line probe assays | Second-line drug LPAs | Box 2.7. WHO recommendations on SL-LPAs (6)","content_type":"box","pages":"33","caption":"Box 2.7. WHO recommendations on SL-LPAs (6)","tokens_est":519,"char_count":2076,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0042","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.3. High-complexity reverse hybridization NAATs","content_type":"text","pages":"34","tokens_est":251,"char_count":1002,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0043","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.3. High-complexity reverse hybridization NAATs | Box 2.8. WHO recommendation on HC- rNAATs (6)","content_type":"box","pages":"34","caption":"Box 2.8. WHO recommendation on HC- rNAATs (6)","tokens_est":119,"char_count":476,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0044","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"34","tokens_est":267,"char_count":1068,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0045","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Fig. 2.2. Process of testing, from sample to result report, for targeted NGS","content_type":"figure","pages":"34-35","caption":"Fig. 2.2. Process of testing, from sample to result report, for targeted NGS","tokens_est":37,"char_count":146,"has_attachment":true,"attachment_id":"Fig. 2.2.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 2.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0046","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"35","tokens_est":208,"char_count":831,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0047","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Table 2.8. List of targeted NGS solutions and drugs for which WHO recommends their use","content_type":"table","pages":"35","caption":"Table 2.8. List of targeted NGS solutions and drugs for which WHO recommends their use","tokens_est":47,"char_count":464,"has_attachment":true,"attachment_id":"Table 2.8.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.8..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0048","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions","content_type":"text","pages":"35","tokens_est":84,"char_count":336,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0049","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","content_type":"box","pages":"35","caption":"Box 2.9. WHO policy statement on targeted NGS solutions for detection of DR-TB, 2025","tokens_est":847,"char_count":3386,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0050","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Implementation considerations","content_type":"text","pages":"35-36","tokens_est":756,"char_count":3024,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0051","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.4. Follow-on diagnostic tests for detection of additional drug resistance | 2.4.4. Targeted NGS end-to-end solutions | Box 2.10. WHO recommendations on targeted NGS (6)","content_type":"box","pages":"36-37","caption":"Box 2.10. WHO recommendations on targeted NGS (6)","tokens_est":846,"char_count":3384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0052","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST","content_type":"text","pages":"37-38","tokens_est":430,"char_count":1720,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0053","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","content_type":"box","pages":"38","caption":"Box 2.11. WHO policy statement on the assessment of critical concentrations for pretomanid and cycloserine , 2023","tokens_est":451,"char_count":1802,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0054","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Implementation considerations","content_type":"text","pages":"38","tokens_est":212,"char_count":847,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0055","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Further research","content_type":"text","pages":"38-39","tokens_est":707,"char_count":2826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0056","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Table 2.9. Critical concentrations for first-line medicines recommended for the treatment of drug-susceptible TB","content_type":"table","pages":"40","caption":"Table 2.9. Critical concentrations for first-line medicines recommended for the treatment of drug-susceptible TB","tokens_est":67,"char_count":1904,"has_attachment":true,"attachment_id":"Table 2.9.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.9..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0057","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.1. Phenotypic DST | Table 2.10. Critical concentrations and clinical breakpoints for medicines recommended for the treatment of MDR/RR- TB","content_type":"table","pages":"41","caption":"Table 2.10. Critical concentrations and clinical breakpoints for medicines recommended for the treatment of MDR/RR- TB","tokens_est":71,"char_count":1500,"has_attachment":true,"attachment_id":"Table 2.10.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.10..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0058","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing","content_type":"text","pages":"42","tokens_est":737,"char_count":2946,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0059","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.5. Phenotypic and genotypic drug resistance testing methods | 2.5.2. Whole-genome sequencing | Table 2.11. WHO-recommended-diagnostic approaches, reference methods and clinical interpretation for anti-TB medicines","content_type":"table","pages":"42-55","caption":"Table 2.11. WHO-recommended-diagnostic approaches, reference methods and clinical interpretation for anti-TB medicines","tokens_est":113,"char_count":1969,"has_attachment":true,"attachment_id":"Table 2.11.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.11..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0060","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection","content_type":"text","pages":"56-57","tokens_est":637,"char_count":2548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0061","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | Box 2.12. WHO recommendations on tests for TB infection (6)","content_type":"box","pages":"58","caption":"Box 2.12. WHO recommendations on tests for TB infection (6)","tokens_est":162,"char_count":647,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0062","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care","content_type":"text","pages":"58","tokens_est":181,"char_count":721,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0063","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Fig. 2.3. Simplified four-step person- centred TB infection cascade of care","content_type":"figure","pages":"58-59","caption":"Fig. 2.3. Simplified four-step person- centred TB infection cascade of care","tokens_est":69,"char_count":274,"has_attachment":true,"attachment_id":"Fig. 2.3.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 2.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0064","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection?","content_type":"text","pages":"59","tokens_est":158,"char_count":632,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0065","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Box 2.13. Groups that WHO recommends should receive TPT (6)","content_type":"box","pages":"59","caption":"Box 2.13. Groups that WHO recommends should receive TPT (6)","tokens_est":305,"char_count":1217,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0066","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Household contacts of people with TB (regardless of HIV status)","content_type":"text","pages":"59","tokens_est":159,"char_count":633,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0067","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.1. The TB infection cascade of care | Who should be tested for TB infection? | Other people at risk of TB","content_type":"text","pages":"59","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0068","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.2. TB infection skin test using tuberculin","content_type":"text","pages":"60","tokens_est":357,"char_count":1428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0069","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.3. TB infection skin tests using Mtb -specific antigens","content_type":"text","pages":"60","tokens_est":251,"char_count":1004,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0070","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.3. TB infection skin tests using Mtb -specific antigens | Table 2.12. Comparison of Mtb -specific infection skin tests","content_type":"table","pages":"61","caption":"Table 2.12. Comparison of Mtb -specific infection skin tests","tokens_est":30,"char_count":267,"has_attachment":true,"attachment_id":"Table 2.12.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.12..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0071","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays","content_type":"text","pages":"62","tokens_est":276,"char_count":1104,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0072","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Box 2.14. WHO policy statement on IGRAs, 2025","content_type":"box","pages":"62","caption":"Box 2.14. WHO policy statement on IGRAs, 2025","tokens_est":945,"char_count":3777,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0073","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Implementation considerations","content_type":"text","pages":"62","tokens_est":403,"char_count":1610,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0074","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Further research","content_type":"text","pages":"62-63","tokens_est":633,"char_count":2531,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0075","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.6. Tests for TB infection | 2.6.4. Interferon-gamma release assays | Table 2.13. Comparison of IGRA tests","content_type":"table","pages":"64","caption":"Table 2.13. Comparison of IGRA tests","tokens_est":40,"char_count":413,"has_attachment":true,"attachment_id":"Table 2.13.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_2.13..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0076","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.7. Tests WHO recommends against using or recommends limited usage","content_type":"text","pages":"65","tokens_est":338,"char_count":1352,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0077","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"2. TB tests with WHO recommendations | 2.7. Tests WHO recommends against using or recommends limited usage | Box 2.15. WHO recommendations on the use of the TST and IGRAs for the diagnosis of TB disease (6)","content_type":"box","pages":"65","caption":"Box 2.15. WHO recommendations on the use of the TST and IGRAs for the diagnosis of TB disease (6)","tokens_est":102,"char_count":407,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0078","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.1. Epidemiological considerations","content_type":"text","pages":"66","tokens_est":194,"char_count":775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0079","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations","content_type":"text","pages":"66-67","tokens_est":748,"char_count":2990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0080","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","content_type":"box","pages":"67","caption":"Box 3.1. Selection of tests based on prevalence, sensitivity and specificity","tokens_est":539,"char_count":2155,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0081","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Box 3.2. Effect of screening with CXR","content_type":"box","pages":"67","caption":"Box 3.2. Effect of screening with CXR","tokens_est":215,"char_count":858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0082","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.1. Performance of mWRDs for the detection of TB in adults with signs and symptoms being evaluated for pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence out of 1000)","content_type":"table","pages":"68","caption":"Table 3.1 provides examples of population-level projections of the results of testing with automated NAATs (low complexity and moderate complexity) and manual NAATs (low complexity) in settings with different levels of TB prevalence, based on pooled sensitivity and specificity estimates that were extracted from the WHO consolidated guidelines on tuberculosis:","tokens_est":129,"char_count":1141,"has_attachment":true,"attachment_id":"Table 3.1","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.1.csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0083","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.2. Performance of molecular tests for the detection of RIF resistance in adults with signs and symptoms being evaluated for pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of RIF resistance out of 1000)","content_type":"table","pages":"69","caption":"Table 3.2. Performance of molecular tests for the detection of RIF resistance in adults with signs and symptoms being evaluated for pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of RIF resistance out of 1000)","tokens_est":110,"char_count":916,"has_attachment":true,"attachment_id":"Table 3.2.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0084","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.3. Performance of molecular tests for the detection of INH resistance in adults with detected pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of INH resistance out of 1000)","content_type":"table","pages":"70","caption":"Table 3.3. Performance of molecular tests for the detection of INH resistance in adults with detected pulmonary TB a compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of INH resistance out of 1000)","tokens_est":103,"char_count":1070,"has_attachment":true,"attachment_id":"Table 3.3.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0085","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.4. Performance of molecular tests for the detection of FQ resistance in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of FQ resistance out of 1000)","content_type":"table","pages":"71","caption":"Table 3.4. Performance of molecular tests for the detection of FQ resistance in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of FQ resistance out of 1000)","tokens_est":102,"char_count":816,"has_attachment":true,"attachment_id":"Table 3.4.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0086","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.5. Performance of molecular tests for the detection of resistance to other first-line anti-TB medicines in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","content_type":"table","pages":"72","caption":"Table 3.5. Performance of molecular tests for the detection of resistance to other first-line anti-TB medicines in adults with detected pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","tokens_est":126,"char_count":739,"has_attachment":true,"attachment_id":"Table 3.5.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0087","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.2. Pretest probability and test accuracy considerations | Table 3.6. Performance of targeted NGS for the detection of resistance to anti-TB medicines used to treat MDR/RR-TB in adults with bacteriologically confirmed RIF-resistant pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","content_type":"table","pages":"73","caption":"Table 3.6. Performance of targeted NGS for the detection of resistance to anti-TB medicines used to treat MDR/RR-TB in adults with bacteriologically confirmed RIF-resistant pulmonary TB compared with a microbiological reference standard (absolute number of TP, FP, TN or FN, under a given prevalence of resistance out of 1000)","tokens_est":132,"char_count":1144,"has_attachment":true,"attachment_id":"Table 3.6.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_3.6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0088","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.3. Planning for and implementing quality-assured TB testing services","content_type":"text","pages":"74","tokens_est":599,"char_count":2396,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0089","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"74-75","tokens_est":760,"char_count":3038,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0090","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"75-76","tokens_est":981,"char_count":3923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0091","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.4. Concurrent testing to improve case detection in children and in people (of all ages) living with HIV","content_type":"text","pages":"76","tokens_est":503,"char_count":2010,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0092","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77","tokens_est":839,"char_count":3354,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0093","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.1. What are the advantages and disadvantages of testing for TB infection?","content_type":"text","pages":"77-78","tokens_est":472,"char_count":1886,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0094","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised?","content_type":"text","pages":"78","tokens_est":37,"char_count":148,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0095","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Prior positive TB infection tests","content_type":"text","pages":"78","tokens_est":124,"char_count":494,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0096","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Concomitant or recent vaccines or viral illnesses","content_type":"text","pages":"78-79","tokens_est":285,"char_count":1139,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0097","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Clinical work-up of adults to diagnose TB disease or monitoring of the response to treatment","content_type":"text","pages":"79","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0098","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | History of TST or TBST allergic reactions (but IGRAs may be used)","content_type":"text","pages":"79","tokens_est":237,"char_count":947,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0099","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.5. Testing for TB infection | 3.5.2. When is testing for TB infection not advised? | Challenges with blood collection in young children when using IGRAs (but TBST may be used)","content_type":"text","pages":"79","tokens_est":95,"char_count":380,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0100","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"3. Strategies and considerations for diagnostic testing | 3.6. Multidisease testing considerations","content_type":"text","pages":"79-80","tokens_est":532,"char_count":2128,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0101","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network","content_type":"text","pages":"81","tokens_est":455,"char_count":1817,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0102","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | Fig. 4.1. The 12 benchmarks constituting the WHO standard are divided into four steps along the diagnostic cascade","content_type":"figure","pages":"81-82","caption":"Fig. 4.1. The 12 benchmarks constituting the WHO standard are divided into four steps along the diagnostic cascade","tokens_est":82,"char_count":326,"has_attachment":true,"attachment_id":"Fig. 4.1.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 4.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0103","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.1. Peripheral level","content_type":"text","pages":"82-84","tokens_est":809,"char_count":3236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0104","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.2. Intermediate level","content_type":"text","pages":"84-85","tokens_est":414,"char_count":1655,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0105","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.3. Central level","content_type":"text","pages":"85","tokens_est":270,"char_count":1077,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0106","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.3. Central level | Fig. 4.2. Organization of a TB diagnostic testing network","content_type":"figure","pages":"85","caption":"Fig. 4.2. Organization of a TB diagnostic testing network","tokens_est":135,"char_count":540,"has_attachment":true,"attachment_id":"Fig. 4.2.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 4.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0107","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"4. Placement of diagnostic tests in the tiered laboratory network | 4.4. Structure of network and testing packages","content_type":"text","pages":"86-87","tokens_est":851,"char_count":3404,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0108","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test","content_type":"text","pages":"88","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0109","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.1  Establish a TWG with defined roles and responsibilities","content_type":"text","pages":"88-89","tokens_est":569,"char_count":2274,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0110","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.2  Review WHO policies and available technical and implementation guides","content_type":"text","pages":"89","tokens_est":152,"char_count":605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0111","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.3  Define immediate and future purposes of the test","content_type":"text","pages":"89","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0112","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.4  Update national diagnostic algorithm and guidelines","content_type":"text","pages":"90","tokens_est":224,"char_count":893,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0113","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.5  Perform a situational analysis, including biosafety","content_type":"text","pages":"90","tokens_est":253,"char_count":1011,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0114","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.1. Area 1  Policies, budgeting and planning | Step 1.6  Develop a costed operational plan for phased implementation","content_type":"text","pages":"90","tokens_est":336,"char_count":1342,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0115","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.1  Complete national regulatory processes","content_type":"text","pages":"91","tokens_est":282,"char_count":1128,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0116","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.2  Determine importation requirements","content_type":"text","pages":"91","tokens_est":120,"char_count":477,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0117","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.2. Area 2  Regulatory issues | Step 2.3  Conduct country validation and verification studies, as required","content_type":"text","pages":"91-92","tokens_est":639,"char_count":2554,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0118","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.1  Select, procure, install and set up equipment","content_type":"text","pages":"92-93","tokens_est":578,"char_count":2309,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0119","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.2  Verify and maintain instruments","content_type":"text","pages":"93","tokens_est":473,"char_count":1891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0120","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.3. Area 3  Equipment | Step 3.3  Assess site readiness and ensure a safe and functional testing site","content_type":"text","pages":"93-94","tokens_est":343,"char_count":1369,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0121","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.1  Review forecasting, ordering and distribution procedures","content_type":"text","pages":"94","tokens_est":448,"char_count":1791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0122","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.4. Area 4  Supply chain | Step 4.2  Develop procedures to monitor reagent quality and shelf life","content_type":"text","pages":"94-95","tokens_est":449,"char_count":1794,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0123","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.1  Develop SOPs","content_type":"text","pages":"95","tokens_est":267,"char_count":1068,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0124","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.5. Area 5  Procedures | Step 5.2  Update clinical procedures and strengthen the clinicallaboratory interface","content_type":"text","pages":"96","tokens_est":351,"char_count":1404,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0125","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.1  Develop the use of digital data and diagnostics connectivity","content_type":"text","pages":"96-97","tokens_est":443,"char_count":1770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0126","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.2  Develop procedures for data backup, security and confidentiality","content_type":"text","pages":"97","tokens_est":189,"char_count":756,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0127","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.6. Area 6  Digital data | Step 6.3  Data requirements for targeted NGS","content_type":"text","pages":"97","tokens_est":103,"char_count":409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0128","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.1  Implement a comprehensive QA system","content_type":"text","pages":"97-98","tokens_est":204,"char_count":815,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0129","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.2  Establish and monitor QC","content_type":"text","pages":"98","tokens_est":326,"char_count":1303,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0130","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.3  Develop an EQA programme","content_type":"text","pages":"98-99","tokens_est":772,"char_count":3087,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0131","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.7. Area 7  Quality assurance, control and assessment | Step 7.4  Monitor and analyse quality indicators","content_type":"text","pages":"99-100","tokens_est":443,"char_count":1770,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0132","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.1  Review and revise request for examination and reporting forms","content_type":"text","pages":"100-101","tokens_est":816,"char_count":3261,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0133","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.8. Area 8  Recording and reporting | Step 8.2  Review and revise laboratory and clinical registers","content_type":"text","pages":"101","tokens_est":157,"char_count":625,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0134","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.1  Develop terms of reference and position descriptions","content_type":"text","pages":"101","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0135","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.2  Develop and implement a training curriculum and strategy","content_type":"text","pages":"101-102","tokens_est":445,"char_count":1779,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0136","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.3  Assess and document the competence of staff","content_type":"text","pages":"102","tokens_est":163,"char_count":651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0137","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.9. Area 9  Human resource training and competency assessment | Step 9.4  Provide for post-training mentoring and support","content_type":"text","pages":"102","tokens_est":105,"char_count":418,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0138","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.10. Area 10  Monitoring and evaluation | Step 10.1  Monitor implementation of the diagnostic test","content_type":"text","pages":"102","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0139","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"5. Steps and processes for implementing a new diagnostic test | 5.10. Area 10  Monitoring and evaluation | Step 10.2  Monitor and evaluate impact of the diagnostic test","content_type":"text","pages":"103","tokens_est":219,"char_count":876,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0140","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms","content_type":"text","pages":"104-105","tokens_est":782,"char_count":3128,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0141","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | TB screening strategies","content_type":"text","pages":"105","tokens_est":429,"char_count":1713,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0142","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.1. Implementing a new diagnostic algorithm","content_type":"text","pages":"105-106","tokens_est":530,"char_count":2117,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0143","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms","content_type":"text","pages":"106","tokens_est":528,"char_count":2112,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0144","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.2. The cascade of the four model algorithms | Fig. 6.1. The cascade of the four diagnostic algorithms","content_type":"figure","pages":"106-107","caption":"Fig. 6.1. The cascade of the four diagnostic algorithms","tokens_est":208,"char_count":829,"has_attachment":true,"attachment_id":"Fig. 6.1.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0145","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB","content_type":"text","pages":"108","tokens_est":620,"char_count":2478,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0146","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | Fig. 6.2. Algorithm 1: mWRD as the i nitial diagnostic test for T B","content_type":"figure","pages":"108-111","caption":"Fig. 6.2. Algorithm 1: mWRD as the i nitial diagnostic test for T B","tokens_est":2113,"char_count":8450,"has_attachment":true,"attachment_id":"Fig. 6.2.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0147","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"112-113","tokens_est":961,"char_count":3843,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0148","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | General considerations","content_type":"text","pages":"113-114","tokens_est":813,"char_count":3250,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0149","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"114","tokens_est":358,"char_count":1431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0150","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.1. Pathway 1A : All tests are negative","content_type":"figure","pages":"114","caption":"Fig 6.2.1. Pathway 1A : All tests are negative","tokens_est":70,"char_count":279,"has_attachment":true,"attachment_id":"Fig 6.2.1.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0151","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"114-115","tokens_est":384,"char_count":1535,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0152","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.2. Pathway 1B: MTBC detected, and RIF susceptibility confirmed","content_type":"figure","pages":"115","caption":"Fig 6.2.2. Pathway 1B: MTBC detected, and RIF susceptibility confirmed","tokens_est":109,"char_count":434,"has_attachment":true,"attachment_id":"Fig 6.2.2.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.2..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0153","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"115-116","tokens_est":971,"char_count":3882,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0154","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"116","tokens_est":131,"char_count":523,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0155","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.3. Pathway 1C: MTBC detected and RIF resistance detected","content_type":"figure","pages":"116-117","caption":"Fig 6.2.3. Pathway 1C: MTBC detected and RIF resistance detected","tokens_est":88,"char_count":352,"has_attachment":true,"attachment_id":"Fig 6.2.3.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0156","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"117-118","tokens_est":884,"char_count":3533,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0157","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"118-119","tokens_est":478,"char_count":1912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0158","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.4. Pathway 1D: MTBC detected (if Ultra, not trace result) and RIF resistance unknown or indeterminate","content_type":"figure","pages":"119-120","caption":"Fig 6.2.4. Pathway 1D: MTBC detected (if Ultra, not trace result) and RIF resistance unknown or indeterminate","tokens_est":113,"char_count":451,"has_attachment":true,"attachment_id":"Fig 6.2.4.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0159","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"120-121","tokens_est":781,"char_count":3122,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0160","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Fig 6.2.5. Pathway 1E: MTBC detected with trace result, RIF indeterminate","content_type":"figure","pages":"121-122","caption":"Fig 6.2.5. Pathway 1E: MTBC detected with trace result, RIF indeterminate","tokens_est":108,"char_count":429,"has_attachment":true,"attachment_id":"Fig 6.2.5.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig 6.2.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0161","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"122-124","tokens_est":963,"char_count":3851,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0162","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway","content_type":"text","pages":"124-125","tokens_est":229,"char_count":915,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0163","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"125-126","tokens_est":970,"char_count":3878,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0164","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"126-127","tokens_est":942,"char_count":3767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0165","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.3. Algorithm 1  WRDs as initial diagnostic tests for TB | 6.3.1. Decision pathway for Algorithm 1  WRD as the initial diagnostic test for TB | Decision pathway | Interpretation of discordant results","content_type":"text","pages":"127-128","tokens_est":611,"char_count":2442,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0166","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"128","tokens_est":349,"char_count":1394,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0167","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | General considerations","content_type":"text","pages":"129","tokens_est":379,"char_count":1514,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0168","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Fig. 6.3. Treatment option overview","content_type":"figure","pages":"129-130","caption":"Fig. 6.3. Treatment option overview","tokens_est":220,"char_count":878,"has_attachment":true,"attachment_id":"Fig. 6.3.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.3..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0169","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB","content_type":"text","pages":"130-131","tokens_est":695,"char_count":2777,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0170","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Fig. 6.4. Algorithm 2a: DST for MDR/RR-TB using targeted NGS","content_type":"figure","pages":"131-133","caption":"Fig. 6.4. Algorithm 2a: DST for MDR/RR-TB using targeted NGS","tokens_est":669,"char_count":2674,"has_attachment":true,"attachment_id":"Fig. 6.4.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.4..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0171","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"133-134","tokens_est":942,"char_count":3768,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0172","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2a  Testing for BDQ and FQ resistance (Fig. 6.4)","content_type":"text","pages":"134","tokens_est":430,"char_count":1717,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0173","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Fig. 6.5. Algorithm 2b: DST for people with MDR/RR-TB (limited or no targeted NGS capacity)","content_type":"figure","pages":"134-136","caption":"Fig. 6.5. Algorithm 2b: DST for people with MDR/RR-TB (limited or no targeted NGS capacity)","tokens_est":830,"char_count":3317,"has_attachment":true,"attachment_id":"Fig. 6.5.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.5..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0174","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"136-137","tokens_est":946,"char_count":3783,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0175","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.4. Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | 6.4.1. Decision pathway for Algorithm 2  DST for second-line drugs for people with MDR/RR-TB | Decision pathway for Algorithm 2b  Testing for FQ resistance (Fig. 6.5)","content_type":"text","pages":"137-138","tokens_est":392,"char_count":1568,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0176","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"138","tokens_est":295,"char_count":1180,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0177","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"138-139","tokens_est":653,"char_count":2611,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0178","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Fig. 6.6. Algorithm 3: Follow-on testing for people with RIF-susceptible TB at risk of resistance to other drugs","content_type":"figure","pages":"139-141","caption":"Fig. 6.6. Algorithm 3: Follow-on testing for people with RIF-susceptible TB at risk of resistance to other drugs","tokens_est":810,"char_count":3240,"has_attachment":true,"attachment_id":"Fig. 6.6.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.6..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0179","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Decision pathway for Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs","content_type":"text","pages":"141-142","tokens_est":808,"char_count":3232,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0180","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations | Table 6.1. Treatment modifications and follow-on DST for Hr -TB based on results from targeted NGS","content_type":"table","pages":"142","caption":"Table 6.1. Treatment modifications and follow-on DST for Hr -TB based on results from targeted NGS","tokens_est":55,"char_count":717,"has_attachment":true,"attachment_id":"Table 6.1.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_6.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0181","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"142-144","tokens_est":967,"char_count":3868,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0182","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.5. Algorithm 3  Follow-on testing for individuals with RIF-susceptible TB at risk of resistance to other drugs | 6.5.1. General considerations","content_type":"text","pages":"144","tokens_est":295,"char_count":1177,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0183","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"144-145","tokens_est":963,"char_count":3852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0184","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.6. Discordant results | Interpretation of discordant results","content_type":"text","pages":"145-146","tokens_est":374,"char_count":1495,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0185","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"146-147","tokens_est":977,"char_count":3908,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0186","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection | Fig. 6.7. Algorithm for person- centred TB infection care; integrated infection and disease assessment where testing for TB infection is available a and recommended","content_type":"figure","pages":"147-148","caption":"Fig. 6.7. Algorithm for person- centred TB infection care; integrated infection and disease assessment where testing for TB infection is available a and recommended","tokens_est":433,"char_count":1732,"has_attachment":true,"attachment_id":"Fig. 6.7.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.7..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0187","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.7. Algorithm 4  Testing for TB infection","content_type":"text","pages":"148-149","tokens_est":268,"char_count":1071,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0188","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations","content_type":"text","pages":"149","tokens_est":232,"char_count":926,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0189","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations | Fig. 6.8. Scenario 1: High TB/HIV setting","content_type":"figure","pages":"149-150","caption":"Fig. 6.8. Scenario 1: High TB/HIV setting","tokens_est":92,"char_count":367,"has_attachment":true,"attachment_id":"Fig. 6.8.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.8..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0190","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations | Fig. 6.9. Scenario 2: High Hr -TB setting","content_type":"figure","pages":"150-151","caption":"Fig. 6.9. Scenario 2: High Hr -TB setting","tokens_est":11,"char_count":41,"has_attachment":true,"attachment_id":"Fig. 6.9.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.9..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0191","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"6. Model algorithms | 6.8. Illustrative algorithm combinations | Fig. 6.10. Scenario 3: High MDR/RR-TB setting","content_type":"figure","pages":"151-152","caption":"Fig. 6.10. Scenario 3: High MDR/RR-TB setting","tokens_est":136,"char_count":544,"has_attachment":true,"attachment_id":"Fig. 6.10.","attachment_path":"../figures/WHO_TB_handbook_module3_diagnosis_2025/Fig. 6.10..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0192","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"160-162","tokens_est":952,"char_count":3807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0193","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 1. Budgetary considerations for implementing a new diagnostic test","content_type":"text","pages":"162","tokens_est":353,"char_count":1410,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0194","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations","content_type":"text","pages":"163","tokens_est":563,"char_count":2251,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0195","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 2. Drug susceptibility testing methods and critical concentrations | Table A2.1. Availability of pure powders from GDF and other manufacturers","content_type":"table","pages":"164","caption":"Table A2.1. Availability of pure powders from GDF and other manufacturers","tokens_est":51,"char_count":770,"has_attachment":true,"attachment_id":"Table A2.1.","attachment_path":"../tables/WHO_TB_handbook_module3_diagnosis_2025/Table_A2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0196","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"166-167","tokens_est":956,"char_count":3823,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0197","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 3. Implementation of next-generation sequencing technologies","content_type":"text","pages":"167-168","tokens_est":455,"char_count":1818,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0198","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description","content_type":"text","pages":"169","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0199","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 1. TB Screening check","content_type":"text","pages":"169","tokens_est":317,"char_count":1266,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0200","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 2. Explain the administration of TST or TBST","content_type":"text","pages":"169-170","tokens_est":253,"char_count":1010,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0201","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 3. Prepare for the administration of TST or TBST","content_type":"text","pages":"170","tokens_est":125,"char_count":500,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0202","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 4. Select site for injection","content_type":"text","pages":"170","tokens_est":206,"char_count":822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0203","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 5. Prepare the syringe","content_type":"text","pages":"170","tokens_est":175,"char_count":697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0204","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 6. Clean the injection site","content_type":"text","pages":"171","tokens_est":196,"char_count":782,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0205","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 7. Administer the injection","content_type":"text","pages":"171","tokens_est":284,"char_count":1133,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0206","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 8. After the injection","content_type":"text","pages":"171","tokens_est":108,"char_count":432,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0207","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 9. Take photographs (for mHealth  if applicable)","content_type":"text","pages":"172","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0208","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 10. Provide post-TST care","content_type":"text","pages":"172","tokens_est":303,"char_count":1211,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0209","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 11. Arrange for the result to be read","content_type":"text","pages":"172","tokens_est":156,"char_count":624,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0210","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A1  Test administration | Step 12. Record the result and document details","content_type":"text","pages":"172","tokens_est":191,"char_count":761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0211","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 1. Seeing the patient","content_type":"text","pages":"173","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0212","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 2. Re-check symptoms","content_type":"text","pages":"173","tokens_est":201,"char_count":803,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0213","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 3. Place and position of patient for reading","content_type":"text","pages":"173","tokens_est":71,"char_count":281,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0214","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 4. Inspection of injection site","content_type":"text","pages":"173","tokens_est":306,"char_count":1221,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0215","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 5. Demarcation of induration","content_type":"text","pages":"174","tokens_est":283,"char_count":1132,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0216","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 6. Measurement","content_type":"text","pages":"174-175","tokens_est":220,"char_count":877,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0217","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 7. Post-TST care","content_type":"text","pages":"175","tokens_est":158,"char_count":631,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0218","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 8. Management of results","content_type":"text","pages":"175","tokens_est":216,"char_count":864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0219","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 9. Recording and registration","content_type":"text","pages":"175","tokens_est":253,"char_count":1012,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module3_diagnosis_2025|0220","doc_id":"WHO_TB_handbook_module3_diagnosis_2025","section_path":"Annex 4. Skin tests for tuberculosis infection  detailed description | A2  Reading of TST or TBST result | Step 9. Recording and registration | Global Programme on Tuberculosis & Lung Health World Health Organization","content_type":"text","pages":"177","tokens_est":37,"char_count":145,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module3_diagnosis_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0001","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms","content_type":"text","pages":"1-2","tokens_est":818,"char_count":3271,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0002","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Abbreviations and acronyms | TB medicines","content_type":"text","pages":"3","tokens_est":114,"char_count":455,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0003","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"3-4","tokens_est":927,"char_count":3707,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0004","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Definitions","content_type":"text","pages":"4-5","tokens_est":869,"char_count":3474,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0005","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary","content_type":"text","pages":"6","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0006","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Chapter 1. Drug-susceptible TB treatment","content_type":"text","pages":"6","tokens_est":135,"char_count":540,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0007","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Chapter 2. Drug-resistant TB treatment","content_type":"text","pages":"6","tokens_est":119,"char_count":473,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0008","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Chapter 3. Tuberculosis care and support","content_type":"text","pages":"6","tokens_est":98,"char_count":390,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0009","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Executive summary | Annexes","content_type":"text","pages":"6","tokens_est":109,"char_count":433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0010","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction","content_type":"text","pages":"8","tokens_est":291,"char_count":1164,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0011","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"8-9","tokens_est":288,"char_count":1151,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0012","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | Treatment of DS-TB using 4-month regimens","content_type":"text","pages":"9","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0013","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | DS-TB treatment and antiretroviral therapy in people living with HIV","content_type":"text","pages":"9","tokens_est":153,"char_count":609,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0014","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 1. Introduction | WHO recommendations on DS-TB treatment | The use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"9","tokens_est":119,"char_count":474,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0015","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"9-10","tokens_est":991,"char_count":3962,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0016","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.1 TB diagnostics and DST","content_type":"text","pages":"10-11","tokens_est":241,"char_count":961,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0017","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.2 Care and support during TB treatment","content_type":"text","pages":"11","tokens_est":142,"char_count":566,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0018","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"11-12","tokens_est":594,"char_count":2376,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0019","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | Table 1.2.1. Guide for regimen selection for DS-TB","content_type":"table","pages":"12-17","caption":"Table 1.2.1. Guide for regimen selection for DS-TB","tokens_est":36,"char_count":378,"has_attachment":true,"attachment_id":"Table 1.2.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.2.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0020","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"17","tokens_est":275,"char_count":1097,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0021","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | Box 2.1. Definition of non-severe pulmonary TB","content_type":"box","pages":"17","caption":"Box 2.1. Definition of non-severe pulmonary TB","tokens_est":94,"char_count":376,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0022","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB","content_type":"text","pages":"17-18","tokens_est":671,"char_count":2683,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0023","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | 6-month regimen","content_type":"text","pages":"18","tokens_est":70,"char_count":278,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0024","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 2. Key considerations in DS-TB treatment | 2.3 Options in treatment of DS-TB | 4-month regimens","content_type":"text","pages":"18-19","tokens_est":218,"char_count":871,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0025","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen","content_type":"text","pages":"20","tokens_est":949,"char_count":3793,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0026","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.1 Eligibility","content_type":"text","pages":"20","tokens_est":234,"char_count":934,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0027","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.2 Composition and duration of the regimen 2HRZE/4HR","content_type":"text","pages":"20-21","tokens_est":483,"char_count":1929,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0028","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.3 Considerations for implementation","content_type":"text","pages":"21-22","tokens_est":736,"char_count":2942,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0029","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups","content_type":"text","pages":"22","tokens_est":64,"char_count":255,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0030","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups | 3.4.1 People living with HIV","content_type":"text","pages":"22","tokens_est":364,"char_count":1454,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0031","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.4 Subgroups | 3.4.2 Children","content_type":"text","pages":"22-23","tokens_est":278,"char_count":1111,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0032","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 3. Treatment of DS-TB using the 6-month regimen | 3.5 Treatment monitoring","content_type":"text","pages":"23","tokens_est":412,"char_count":1646,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0033","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen","content_type":"text","pages":"24","tokens_est":470,"char_count":1879,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0034","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.1 Eligibility","content_type":"text","pages":"24","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0035","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.2 Composition and duration of the regimen","content_type":"text","pages":"24-25","tokens_est":373,"char_count":1492,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0036","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation","content_type":"text","pages":"25","tokens_est":87,"char_count":345,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0037","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | DST","content_type":"text","pages":"25","tokens_est":275,"char_count":1099,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0038","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Treatment support","content_type":"text","pages":"25","tokens_est":114,"char_count":454,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0039","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Pill burden","content_type":"text","pages":"26","tokens_est":84,"char_count":333,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0040","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Cost of medicines","content_type":"text","pages":"26","tokens_est":140,"char_count":558,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0041","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Administration of the shorter regimen with food","content_type":"text","pages":"26","tokens_est":217,"char_count":865,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0042","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Training of health care workers","content_type":"text","pages":"26","tokens_est":79,"char_count":316,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0043","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.3 Considerations for implementation | Criteria guiding the choice of regimen","content_type":"text","pages":"26","tokens_est":65,"char_count":258,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0044","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups","content_type":"text","pages":"26-27","tokens_est":249,"char_count":996,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0045","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used","content_type":"text","pages":"27","tokens_est":59,"char_count":234,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0046","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | People living with HIV","content_type":"text","pages":"27","tokens_est":59,"char_count":234,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0047","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | People with diabetes","content_type":"text","pages":"27","tokens_est":182,"char_count":726,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0048","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | People with extensive pulmonary TB disease","content_type":"text","pages":"27","tokens_est":107,"char_count":425,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0049","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.1 Subgroups in which the shorter regimen can be used | Children and adolescents","content_type":"text","pages":"27-28","tokens_est":140,"char_count":559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0050","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended","content_type":"text","pages":"28","tokens_est":68,"char_count":272,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0051","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Patients weighing less than 40 kg","content_type":"text","pages":"28","tokens_est":58,"char_count":232,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0052","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Patients with extrapulmonary TB","content_type":"text","pages":"28","tokens_est":50,"char_count":197,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0053","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | PLHIV with a CD4 count of less than 100 cells/mm 3","content_type":"text","pages":"28","tokens_est":45,"char_count":180,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0054","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Children and adolescents aged under 12 years","content_type":"text","pages":"28","tokens_est":38,"char_count":152,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0055","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.4 Subgroups | 4.4.2 Subgroups in which the regimen is not recommended | Pregnant, breastfeeding and postpartum women","content_type":"text","pages":"28","tokens_est":43,"char_count":169,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0056","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 4. Treatment of DS-TB using the 4-month 2HPMZ/2HPM regimen | 4.5 Treatment monitoring","content_type":"text","pages":"28-29","tokens_est":359,"char_count":1433,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0057","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen","content_type":"text","pages":"29-30","tokens_est":421,"char_count":1684,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0058","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility","content_type":"text","pages":"30","tokens_est":26,"char_count":102,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0059","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.1 Eligibility | Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","content_type":"box","pages":"30-31","caption":"Box 5.1. Eligibility criteria for the 4-month regimen m (2HRZ(E)/2HR) in children and adolescents aged between 3 months and 16 years, in various settings","tokens_est":825,"char_count":3299,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0060","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.2 Composition and duration of the regimen","content_type":"text","pages":"31","tokens_est":586,"char_count":2341,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0061","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Assessing severity of disease","content_type":"text","pages":"32","tokens_est":546,"char_count":2184,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0062","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Continuum between TB infection and disease","content_type":"text","pages":"32","tokens_est":122,"char_count":487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0063","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Contact investigation","content_type":"text","pages":"32","tokens_est":59,"char_count":236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0064","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Child-friendly formulations","content_type":"text","pages":"33","tokens_est":73,"char_count":289,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0065","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.3 Considerations for implementation | Training of health care workers","content_type":"text","pages":"33","tokens_est":158,"char_count":629,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0066","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.1 Subgroups in which the regimen is recommended | Children with peripheral lymph node TB","content_type":"text","pages":"33","tokens_est":187,"char_count":746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0067","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.1 Subgroups in which the regimen is recommended | Children and adolescents living with HIV","content_type":"text","pages":"33","tokens_est":341,"char_count":1363,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0068","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.4 Subgroups | 5.4.2 Subgroups in which the regimen is not recommended | Children with severe acute malnutrition","content_type":"text","pages":"34","tokens_est":125,"char_count":499,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0069","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 5. Treatment of DS-TB using the 4-month 2HRZ(E)/2HR regimen | 5.5 Treatment monitoring","content_type":"text","pages":"34-36","tokens_est":728,"char_count":2912,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0070","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV","content_type":"text","pages":"37","tokens_est":255,"char_count":1019,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0071","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.1 Eligibility","content_type":"text","pages":"37","tokens_est":78,"char_count":312,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0072","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.2 Composition and duration of the regimen","content_type":"text","pages":"37-38","tokens_est":478,"char_count":1909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0073","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.3 Considerations for implementation","content_type":"text","pages":"38","tokens_est":243,"char_count":970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0074","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 6. Treatment of DS-TB in people living with HIV | 6.4 Treatment monitoring","content_type":"text","pages":"38","tokens_est":83,"char_count":332,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0075","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB","content_type":"text","pages":"38","tokens_est":397,"char_count":1585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0076","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.1 Eligibility","content_type":"text","pages":"39","tokens_est":196,"char_count":781,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0077","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"39-40","tokens_est":792,"char_count":3168,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0078","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.3 Use of adjuvant steroids in the treatment of tuberculous meningitis and pericarditis","content_type":"text","pages":"40","tokens_est":569,"char_count":2274,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0079","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 7. Treatment of extrapulmonary TB | 7.4 Considerations for implementation","content_type":"text","pages":"40-41","tokens_est":351,"char_count":1401,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0080","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations","content_type":"text","pages":"41","tokens_est":61,"char_count":242,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0081","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes","content_type":"text","pages":"41-42","tokens_est":675,"char_count":2697,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0082","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.1 Diabetes | Implementation considerations","content_type":"text","pages":"42","tokens_est":244,"char_count":976,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0083","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy","content_type":"text","pages":"42-43","tokens_est":746,"char_count":2984,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0084","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.2 Pregnancy | Implementation considerations","content_type":"text","pages":"43","tokens_est":249,"char_count":994,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0085","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people","content_type":"text","pages":"44","tokens_est":835,"char_count":3338,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0086","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.3 Older people | Implementation considerations","content_type":"text","pages":"45","tokens_est":248,"char_count":990,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0087","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.4 Chronic renal failure","content_type":"text","pages":"45-46","tokens_est":606,"char_count":2422,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0088","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.4 Chronic renal failure | Implementation considerations","content_type":"text","pages":"46","tokens_est":132,"char_count":528,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0089","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"46-47","tokens_est":683,"char_count":2729,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0090","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease | Table 1.8.1. ChildTurcottePugh score parameters","content_type":"table","pages":"47","caption":"Table 1.8.1. ChildTurcottePugh score parameters","tokens_est":26,"char_count":148,"has_attachment":true,"attachment_id":"Table 1.8.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.8.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0091","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease | Table 1.8.2. Estimated survival at 1 and 2 years based on ChildTurcottePugh","content_type":"table","pages":"47","caption":"Table 1.8.2. Estimated survival at 1 and 2 years based on ChildTurcottePugh","tokens_est":42,"char_count":175,"has_attachment":true,"attachment_id":"Table 1.8.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.8.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0092","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease","content_type":"text","pages":"47","tokens_est":270,"char_count":1077,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0093","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 8. Treatment of DS-TB in special situations | 8.5 Chronic liver disease | Implementation considerations","content_type":"text","pages":"48","tokens_est":172,"char_count":685,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0094","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response","content_type":"text","pages":"48","tokens_est":395,"char_count":1579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0095","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.1 Clinical examination","content_type":"text","pages":"48-49","tokens_est":494,"char_count":1973,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0096","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.2 Chest radiography","content_type":"text","pages":"49","tokens_est":263,"char_count":1052,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0097","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"49-50","tokens_est":878,"char_count":3512,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0098","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.3 Sputum smear and culture","content_type":"text","pages":"50","tokens_est":264,"char_count":1055,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0099","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | Table 1.9.1. Summary of activities for monitoring treatment response","content_type":"table","pages":"51","caption":"Table 1.9.1. Summary of activities for monitoring treatment response","tokens_est":31,"char_count":283,"has_attachment":true,"attachment_id":"Table 1.9.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.9.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0100","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected","content_type":"text","pages":"51-52","tokens_est":149,"char_count":595,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0101","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Confirm treatment","content_type":"text","pages":"52","tokens_est":29,"char_count":116,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0102","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Look for undetected comorbidities","content_type":"text","pages":"52","tokens_est":133,"char_count":529,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0103","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review the bacteriological data","content_type":"text","pages":"52","tokens_est":111,"char_count":444,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0104","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review the DST","content_type":"text","pages":"52","tokens_est":41,"char_count":161,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0105","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review CXR","content_type":"text","pages":"52","tokens_est":42,"char_count":167,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0106","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Review treatment regimen","content_type":"text","pages":"52","tokens_est":93,"char_count":369,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0107","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 9. Monitoring treatment response | 9.4 Assessment of patients when treatment failure is suspected | Consider malabsorption","content_type":"text","pages":"52-53","tokens_est":227,"char_count":907,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0108","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions","content_type":"text","pages":"55","tokens_est":365,"char_count":1458,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0109","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | 10.1 Treatment outcome definitions","content_type":"text","pages":"55-56","tokens_est":586,"char_count":2341,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0110","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | 10.2 Considerations for implementation","content_type":"text","pages":"56","tokens_est":189,"char_count":754,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0111","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 1 : Drug - susceptible TB treatment | 10. Outcome definitions | Table 1.10.1. New definitions of TB treatment outcomes for both DS-TB and DR-TB","content_type":"table","pages":"56-57","caption":"Table 1.10.1. New definitions of TB treatment outcomes for both DS-TB and DR-TB","tokens_est":28,"char_count":1229,"has_attachment":true,"attachment_id":"Table 1.10.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1.10.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0112","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 1. Introduction","content_type":"text","pages":"59","tokens_est":308,"char_count":1229,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0113","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Treatment of drug- resistant TB using 6-month regimens","content_type":"text","pages":"59","tokens_est":154,"char_count":615,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0114","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Treatment of drug-resistant TB using 9-month regimens","content_type":"text","pages":"59-60","tokens_est":238,"char_count":950,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0115","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"60-61","tokens_est":959,"char_count":3834,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0116","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Longer regimens for MDR/RR-TB","content_type":"text","pages":"61-62","tokens_est":217,"char_count":866,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0117","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Regimen for rifampicin-susceptible and isoniazid-resistant TB","content_type":"text","pages":"62","tokens_est":147,"char_count":588,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0118","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Monitoring patient response to MDR/RR-TB treatment using culture","content_type":"text","pages":"62","tokens_est":108,"char_count":431,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0119","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Start of antiretroviral therapy in patients on MDR/RR-TB regimens","content_type":"text","pages":"62","tokens_est":101,"char_count":401,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0120","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Surgery for patients on MDR/RR-TB treatment","content_type":"text","pages":"62","tokens_est":80,"char_count":320,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0121","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 2. WHO recommendations on D R-TB treatment | Hepatitis C virus (HCV) and MDR/RR-TB treatment co-administration","content_type":"text","pages":"62","tokens_est":81,"char_count":321,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0122","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"65-66","tokens_est":956,"char_count":3822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0123","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"66","tokens_est":711,"char_count":2842,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0124","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"66-67","tokens_est":904,"char_count":3616,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0125","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.1 Access to DST","content_type":"text","pages":"67","tokens_est":171,"char_count":683,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0126","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.2 Safety monitoring and management and provision of patient support","content_type":"text","pages":"67-68","tokens_est":339,"char_count":1353,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0127","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.3 Extensive pulmonary TB disease","content_type":"text","pages":"68","tokens_est":147,"char_count":587,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0128","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"68-69","tokens_est":811,"char_count":3243,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0129","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"69","tokens_est":338,"char_count":1349,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0130","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB | Table 2.3.1. Regimen options and factors to be considered for selection of treatment regimens for patients with MDR/RR-TB","content_type":"table","pages":"69-71","caption":"Table 2.3.1. Regimen options and factors to be considered for selection of treatment regimens for patients with MDR/RR-TB","tokens_est":83,"char_count":684,"has_attachment":true,"attachment_id":"Table 2.3.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.3.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0131","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"71-73","tokens_est":868,"char_count":3470,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0132","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB","content_type":"text","pages":"73-74","tokens_est":246,"char_count":982,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0133","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 3. Key considerations in DR-TB treatment | 3.4 Regimen options in the treatment of DR-TB | Fig. 2.3.1. Regimen options for MDR/RR-TB treatment","content_type":"figure","pages":"74","caption":"Fig. 2.3.1. Regimen options for MDR/RR-TB treatment","tokens_est":33,"char_count":130,"has_attachment":true,"attachment_id":"Fig. 2.3.1.","attachment_path":"figures/WHO_TB_handbook_module4_treatment_2025/Fig. 2.3.1..png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0134","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen","content_type":"text","pages":"74-75","tokens_est":953,"char_count":3810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0135","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"75-76","tokens_est":906,"char_count":3621,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0136","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.1 Eligibility","content_type":"text","pages":"76","tokens_est":489,"char_count":1956,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0137","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Composition","content_type":"text","pages":"77","tokens_est":175,"char_count":700,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0138","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing","content_type":"text","pages":"77","tokens_est":286,"char_count":1144,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0139","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing | Table 2.4.1. Dosing of component drugs for adults and adolescents (aged 14 years) for BPaLM and BPaL","content_type":"table","pages":"77","caption":"Table 2.4.1. Dosing of component drugs for adults and adolescents (aged 14 years) for BPaLM and BPaL","tokens_est":31,"char_count":194,"has_attachment":true,"attachment_id":"Table 2.4.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0140","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Dosing","content_type":"text","pages":"77-78","tokens_est":271,"char_count":1083,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0141","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"78","tokens_est":692,"char_count":2767,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0142","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.2 Composition, dosing and duration of the regimen | Duration | Fig. 2.4.1 Duration of treatment with BPaLM and BPaL regimen options","content_type":"figure","pages":"78","caption":"Fig. 2.4.1 Duration of treatment with BPaLM and BPaL regimen options","tokens_est":20,"char_count":78,"has_attachment":true,"attachment_id":"Fig. 2.4.1","attachment_path":"figures/WHO_TB_handbook_module4_treatment_2025/Fig. 2.4.1.png","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0143","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"79","tokens_est":906,"char_count":3623,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0144","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification | Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","content_type":"box","pages":"80","caption":"Box 2.4.1. Examples of changes in linezolid dosing within the BPaLM / BPaL regimen","tokens_est":524,"char_count":2096,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0145","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Linezolid modification","content_type":"text","pages":"80-81","tokens_est":481,"char_count":1923,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0146","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Modification or discontinuation of full BPaLM / BPaL regimen","content_type":"text","pages":"81","tokens_est":165,"char_count":659,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0147","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Temporary cessation of full BPaLM / BPaL regimen","content_type":"text","pages":"81","tokens_est":199,"char_count":796,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0148","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen","content_type":"text","pages":"81-82","tokens_est":559,"char_count":2234,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0149","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Table 2.4.2. Linezolid m odifications options in BPaLM / BPaL","content_type":"table","pages":"82","caption":"Table 2.4.2. Linezolid m odifications options in BPaLM / BPaL","tokens_est":24,"char_count":453,"has_attachment":true,"attachment_id":"Table 2.4.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.4.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0150","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.3 Modifications of treatment | Permanent discontinuation of BPaLM / BPaL and change to another regimen | Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","content_type":"box","pages":"83","caption":"Box 2.4.2. Examples of changes in the BPaLM or BPaL regimen","tokens_est":551,"char_count":2201,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0151","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups","content_type":"text","pages":"83","tokens_est":213,"char_count":852,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0152","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Extensive pulmonary TB","content_type":"text","pages":"83-84","tokens_est":104,"char_count":416,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0153","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"84","tokens_est":195,"char_count":778,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0154","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"84","tokens_est":598,"char_count":2392,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0155","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"84-85","tokens_est":117,"char_count":466,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0156","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.4 Key subgroups | Children and adolescents","content_type":"text","pages":"85","tokens_est":226,"char_count":903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0157","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"85-86","tokens_est":936,"char_count":3741,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0158","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | DST and resistance to the component medicines","content_type":"text","pages":"86","tokens_est":72,"char_count":287,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0159","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | History of exposure to component drugs","content_type":"text","pages":"86","tokens_est":301,"char_count":1201,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0160","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Drugdrug interactions","content_type":"text","pages":"86","tokens_est":124,"char_count":496,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0161","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Cost and costeffectiveness analysis","content_type":"text","pages":"87","tokens_est":302,"char_count":1208,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0162","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.1 The 6-month bedaquiline, pretomanid , linezolid and moxifloxacin ( BPaLM ) regimen | 4.1.5 Implementation considerations | Treatment support","content_type":"text","pages":"87","tokens_est":250,"char_count":998,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0163","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"87-88","tokens_est":663,"char_count":2649,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0164","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen","content_type":"text","pages":"88-89","tokens_est":930,"char_count":3719,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0165","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.1 Eligibility","content_type":"text","pages":"89-90","tokens_est":623,"char_count":2492,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0166","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen","content_type":"text","pages":"90","tokens_est":420,"char_count":1679,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0167","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Composition | BDLLfxC regimen","content_type":"text","pages":"90","tokens_est":154,"char_count":613,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0168","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Composition | BDLLfx regimen","content_type":"text","pages":"90-91","tokens_est":206,"char_count":821,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0169","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Composition | BDLC regimen","content_type":"text","pages":"91","tokens_est":228,"char_count":911,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0170","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing","content_type":"text","pages":"91","tokens_est":60,"char_count":239,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0171","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Bedaquiline","content_type":"text","pages":"91","tokens_est":340,"char_count":1357,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0172","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Delamanid","content_type":"text","pages":"91-92","tokens_est":172,"char_count":687,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0173","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Linezolid","content_type":"text","pages":"92","tokens_est":122,"char_count":485,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0174","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Levofloxacin","content_type":"text","pages":"92","tokens_est":145,"char_count":577,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0175","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Clofazimine","content_type":"text","pages":"92","tokens_est":100,"char_count":398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0176","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Dosing | Pregnancy and postpartum","content_type":"text","pages":"92","tokens_est":127,"char_count":506,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0177","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.2 Composition , dosing and duration of the regimen | Duration","content_type":"text","pages":"94","tokens_est":857,"char_count":3425,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0178","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Drug toxicity","content_type":"text","pages":"94-95","tokens_est":556,"char_count":2224,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0179","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Drug substitution","content_type":"text","pages":"95","tokens_est":126,"char_count":502,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0180","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Missed doses","content_type":"text","pages":"95","tokens_est":193,"char_count":771,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0181","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"96","tokens_est":370,"char_count":1480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0182","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Extensive pulmonary TB and resistance to fluoroquinolones","content_type":"text","pages":"96","tokens_est":426,"char_count":1703,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0183","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"96-97","tokens_est":138,"char_count":550,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0184","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | People living with HIV","content_type":"text","pages":"97","tokens_est":394,"char_count":1575,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0185","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"97-98","tokens_est":535,"char_count":2138,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0186","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"98-99","tokens_est":828,"char_count":3312,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0187","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.4 Key subgroups | Children and adolescents","content_type":"text","pages":"99","tokens_est":211,"char_count":842,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0188","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | DST results","content_type":"text","pages":"99","tokens_est":376,"char_count":1501,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0189","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | History of exposure to component drugs","content_type":"text","pages":"99","tokens_est":226,"char_count":901,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0190","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Management of anaemia and myelosuppression","content_type":"text","pages":"100","tokens_est":893,"char_count":3570,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0191","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | QT-interval prolongation","content_type":"text","pages":"100-101","tokens_est":448,"char_count":1791,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0192","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Treatment interruption","content_type":"text","pages":"101","tokens_est":223,"char_count":891,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0193","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Care and support","content_type":"text","pages":"101-102","tokens_est":475,"char_count":1898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0194","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 4. Treatment of DR-TB using 6-month regimens | 4.2 The 6-month bedaquiline, delamanid, linezolid, levofloxacin and clofazimine ( BDLLfxC ) regimen | 4.2.5 Implementation considerations | Costeffectiveness analysis","content_type":"text","pages":"102","tokens_est":124,"char_count":496,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0195","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens","content_type":"text","pages":"102","tokens_est":131,"char_count":524,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0196","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | Table 2.5.1. Overview of 9-month regimens","content_type":"table","pages":"102-103","caption":"Table 2.5.1. Overview of 9-month regimens","tokens_est":37,"char_count":328,"has_attachment":true,"attachment_id":"Table 2.5.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.5.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0197","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"103-104","tokens_est":940,"char_count":3758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0198","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB","content_type":"text","pages":"104","tokens_est":326,"char_count":1301,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0199","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.1 Eligibility","content_type":"text","pages":"104-105","tokens_est":956,"char_count":3824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0200","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen","content_type":"text","pages":"106","tokens_est":40,"char_count":159,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0201","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Ethionamide variation","content_type":"text","pages":"106","tokens_est":300,"char_count":1199,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0202","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Linezolid variation","content_type":"text","pages":"106","tokens_est":372,"char_count":1487,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0203","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Choice of fluoroquinolone","content_type":"text","pages":"107","tokens_est":193,"char_count":772,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0204","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.2 Composition, dosing and duration of the regimen | Dosing and frequency","content_type":"text","pages":"107","tokens_est":449,"char_count":1795,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0205","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"107-108","tokens_est":823,"char_count":3292,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0206","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment","content_type":"text","pages":"108","tokens_est":248,"char_count":992,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0207","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.3 Modifications of treatment | Discontinuation and change to another treatment regimen","content_type":"text","pages":"108-109","tokens_est":544,"char_count":2174,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0208","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | People living with HIV","content_type":"text","pages":"109","tokens_est":353,"char_count":1409,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0209","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"109-110","tokens_est":857,"char_count":3428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0210","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Children","content_type":"text","pages":"110","tokens_est":210,"char_count":840,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0211","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Pregnant and breastfeeding women","content_type":"text","pages":"111","tokens_est":548,"char_count":2191,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0212","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Extensive TB disease","content_type":"text","pages":"111","tokens_est":178,"char_count":711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0213","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Older patients","content_type":"text","pages":"111-112","tokens_est":201,"char_count":804,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0214","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"112","tokens_est":270,"char_count":1080,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0215","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with diabetes mellitus","content_type":"text","pages":"112","tokens_est":262,"char_count":1048,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0216","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with hepatic dysfunction","content_type":"text","pages":"112","tokens_est":123,"char_count":491,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0217","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with renal failure","content_type":"text","pages":"112-113","tokens_est":138,"char_count":551,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0218","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.4 Key subgroups | Patients with co-morbidities (other than HIV) | Patients with anaemia","content_type":"text","pages":"113","tokens_est":678,"char_count":2711,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0219","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"113-114","tokens_est":649,"char_count":2593,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0220","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | DST results","content_type":"text","pages":"114-115","tokens_est":919,"char_count":3673,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0221","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","content_type":"box","pages":"115-116","caption":"Box 2.5.1. Regimen selection at RR-TB diagnosis  no initial linezolid contraindications","tokens_est":464,"char_count":1853,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0222","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","content_type":"box","pages":"116","caption":"Box 2.5.2. Regimen selection at RR-TB diagnosis  linezolid contraindications","tokens_est":440,"char_count":1759,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0223","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Assessment of extent and severity of TB disease","content_type":"text","pages":"116-117","tokens_est":364,"char_count":1455,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0224","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.1 The 9-month all-oral regimen for MDR/RR-TB | 5.1.5 Implementation considerations | Haematological assessment","content_type":"text","pages":"117","tokens_est":235,"char_count":938,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0225","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"117-118","tokens_est":867,"char_count":3467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0226","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB","content_type":"text","pages":"118-119","tokens_est":950,"char_count":3797,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0227","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.1 Eligibility","content_type":"text","pages":"119-120","tokens_est":663,"char_count":2651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0228","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen","content_type":"text","pages":"120","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0229","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Table 2.5.2. The composition of the three modified 9-month regimens","content_type":"table","pages":"120","caption":"Table 2.5.2. The composition of the three modified 9-month regimens","tokens_est":40,"char_count":169,"has_attachment":true,"attachment_id":"Table 2.5.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.5.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0230","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Dosing and frequency of component medicines","content_type":"text","pages":"120-121","tokens_est":504,"char_count":2015,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0231","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Duration","content_type":"text","pages":"121","tokens_est":254,"char_count":1013,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0232","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.2 Composition, dosing and duration of the regimen | Treatment discontinuation","content_type":"text","pages":"121","tokens_est":314,"char_count":1256,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0233","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups","content_type":"text","pages":"121-122","tokens_est":103,"char_count":410,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0234","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Children","content_type":"text","pages":"122","tokens_est":371,"char_count":1481,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0235","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Pregnancy","content_type":"text","pages":"122","tokens_est":174,"char_count":695,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0236","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Breastfeeding women","content_type":"text","pages":"122","tokens_est":216,"char_count":863,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0237","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | People living with HIV","content_type":"text","pages":"123","tokens_est":163,"char_count":651,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0238","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Pulmonary TB","content_type":"text","pages":"123","tokens_est":185,"char_count":739,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0239","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Extrapulmonary TB","content_type":"text","pages":"123","tokens_est":93,"char_count":372,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0240","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with diabetes mellitus","content_type":"text","pages":"123","tokens_est":146,"char_count":581,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0241","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with hepatic dysfunction","content_type":"text","pages":"123-124","tokens_est":168,"char_count":672,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0242","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with chronic renal insufficiency","content_type":"text","pages":"124","tokens_est":137,"char_count":548,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0243","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.3 Key subgroups | Patients with comorbidities other than HIV | Patients with anaemia","content_type":"text","pages":"124","tokens_est":440,"char_count":1758,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0244","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | DST considerations","content_type":"text","pages":"124","tokens_est":157,"char_count":628,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0245","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Extent of the disease","content_type":"text","pages":"124","tokens_est":28,"char_count":112,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0246","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Drug-drug interactions (DDIs)","content_type":"text","pages":"125","tokens_est":106,"char_count":424,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0247","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen","content_type":"text","pages":"125","tokens_est":63,"char_count":252,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0248","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | Performance based on pyrazinamide sensitivity and resistance","content_type":"text","pages":"125","tokens_est":157,"char_count":627,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0249","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | Hepatotoxicity and discontinuation of pyrazinamide","content_type":"text","pages":"125","tokens_est":401,"char_count":1601,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0250","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Role of pyrazinamide in the modified 9-month regimen | SoC for pyrazinamide management in the modified 9-month regimens","content_type":"text","pages":"125-126","tokens_est":647,"char_count":2585,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0251","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Cost of the modified 9-month regimen","content_type":"text","pages":"126","tokens_est":181,"char_count":722,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0252","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Table 2.5.3. Prices and pill burden of the modified 9-month regimens","content_type":"table","pages":"126","caption":"Table 2.5.3. Prices and pill burden of the modified 9-month regimens","tokens_est":40,"char_count":308,"has_attachment":true,"attachment_id":"Table 2.5.3.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.5.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0253","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 5. Treatment of drug-resistant TB using 9-month regimens | 5.2 The modified 9-month regimens for MDR/RR-TB | 5.2.4 Implementation considerations | Care and support","content_type":"text","pages":"127","tokens_est":656,"char_count":2621,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0254","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens","content_type":"text","pages":"127-128","tokens_est":632,"char_count":2527,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0255","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.1 Eligibility","content_type":"text","pages":"128-129","tokens_est":789,"char_count":3153,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0256","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens","content_type":"text","pages":"129-130","tokens_est":977,"char_count":3905,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0257","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.1 Choice of components for the longer MDR-TB regimens","content_type":"text","pages":"130-131","tokens_est":977,"char_count":3905,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0258","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens","content_type":"text","pages":"131-132","tokens_est":545,"char_count":2180,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0259","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Table 2.6.1. Grouping of medicines recommended for use in longer MDR-TB regimens [a]","content_type":"table","pages":"132","caption":"Table 2.6.1. Grouping of medicines recommended for use in longer MDR-TB regimens [a]","tokens_est":35,"char_count":4889,"has_attachment":true,"attachment_id":"Table 2.6.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.6.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0260","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A","content_type":"text","pages":"132-133","tokens_est":114,"char_count":453,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0261","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Levofloxacin and moxifloxacin","content_type":"text","pages":"133","tokens_est":453,"char_count":1810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0262","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Bedaquiline","content_type":"text","pages":"133-134","tokens_est":526,"char_count":2104,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0263","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group A | Linezolid","content_type":"text","pages":"134","tokens_est":551,"char_count":2202,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0264","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B","content_type":"text","pages":"134","tokens_est":87,"char_count":345,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0265","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B | Clofazimine","content_type":"text","pages":"134-135","tokens_est":373,"char_count":1490,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0266","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group B | Cycloserine","content_type":"text","pages":"135","tokens_est":370,"char_count":1480,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0267","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C","content_type":"text","pages":"135","tokens_est":128,"char_count":510,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0268","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Ethambutol","content_type":"text","pages":"135-136","tokens_est":128,"char_count":509,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0269","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Delamanid","content_type":"text","pages":"136","tokens_est":433,"char_count":1730,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0270","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Pyrazinamide","content_type":"text","pages":"136","tokens_est":203,"char_count":810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0271","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Imipenem cilastatin and meropenem","content_type":"text","pages":"136-137","tokens_est":260,"char_count":1037,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0272","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Amikacin and streptomycin","content_type":"text","pages":"137","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0273","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | Ethionamide and prothionamide","content_type":"text","pages":"137","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0274","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Group C | P- aminosalicylic acid","content_type":"text","pages":"137","tokens_est":148,"char_count":590,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0275","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Other medicines","content_type":"text","pages":"137","tokens_est":36,"char_count":144,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0276","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.2 Medicines used in longer MDR-TB treatment regimens | Other medicines | High-dose isoniazid","content_type":"text","pages":"137-138","tokens_est":563,"char_count":2250,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0277","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.2 Composition and duration of the regimens | 6.2.3 Duration of the regimen","content_type":"text","pages":"138-139","tokens_est":590,"char_count":2360,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0278","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.1 People living with HIV","content_type":"text","pages":"139","tokens_est":71,"char_count":284,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0279","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.2 Children","content_type":"text","pages":"139","tokens_est":235,"char_count":939,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0280","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.3 Pregnant and breastfeeding women","content_type":"text","pages":"139-140","tokens_est":596,"char_count":2384,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0281","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.4 Patients with diabetes mellitus","content_type":"text","pages":"140","tokens_est":246,"char_count":981,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0282","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.3 Key subgroups | 6.3.5 Patients with extrapulmonary TB","content_type":"text","pages":"140","tokens_est":297,"char_count":1187,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0283","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.1 Extensive DR-TB disease","content_type":"text","pages":"140-141","tokens_est":290,"char_count":1157,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0284","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.2 Severe extrapulmonary TB","content_type":"text","pages":"141","tokens_est":223,"char_count":892,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0285","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB meningitis and brain tuberculomas","content_type":"text","pages":"141","tokens_est":329,"char_count":1314,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0286","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in older patients","content_type":"text","pages":"141","tokens_est":189,"char_count":753,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0287","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB patients with renal failure","content_type":"text","pages":"142","tokens_est":145,"char_count":579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0288","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients with anaemia","content_type":"text","pages":"142","tokens_est":202,"char_count":807,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0289","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in malnourished patients","content_type":"text","pages":"142","tokens_est":368,"char_count":1471,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0290","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients with hepatitis B or C","content_type":"text","pages":"142","tokens_est":68,"char_count":272,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0291","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients with depression","content_type":"text","pages":"142-143","tokens_est":214,"char_count":855,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0292","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.4 Implementation considerations and treatment in special situations | 6.4.3 DR-TB in different patient groups | DR-TB in patients who present with alcohol or other substances abuse","content_type":"text","pages":"143","tokens_est":186,"char_count":743,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0293","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.5 Treatment monitoring","content_type":"text","pages":"143","tokens_est":233,"char_count":930,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0294","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 6. Treatment of drug-resistant TB using longer regimens | 6.5 Treatment monitoring | Table 2.6.2. Summary algorithm for longer MDR-TB regimen composition in commonplace situations of resistance pattern or contraindication","content_type":"table","pages":"143-147","caption":"Table 2.6.2. Summary algorithm for longer MDR-TB regimen composition in commonplace situations of resistance pattern or contraindication","tokens_est":105,"char_count":2304,"has_attachment":true,"attachment_id":"Table 2.6.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.6.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0295","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB","content_type":"text","pages":"149","tokens_est":343,"char_count":1370,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0296","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.1 Eligibility","content_type":"text","pages":"149-150","tokens_est":786,"char_count":3141,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0297","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"150","tokens_est":597,"char_count":2386,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0298","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen | Box 2.7.1. Evaluation of a typical scenario  a delayed DST result in a patient on a first-line regimen","content_type":"box","pages":"151","caption":"Box 2.7.1. Evaluation of a typical scenario  a delayed DST result in a patient on a first-line regimen","tokens_est":358,"char_count":1430,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0299","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.2 Composition and duration of the regimen","content_type":"text","pages":"151","tokens_est":81,"char_count":322,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0300","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.3 Considerations for implementation","content_type":"text","pages":"151-152","tokens_est":895,"char_count":3579,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0301","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 7. Regimen for rifampicin susceptible and isoniazid resistant TB | 7.4 Treatment monitoring","content_type":"text","pages":"152-153","tokens_est":958,"char_count":3829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0302","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"155","tokens_est":860,"char_count":3439,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0303","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.1 Surgery in the treatment of MDR/XDR-TB","content_type":"text","pages":"155-156","tokens_est":457,"char_count":1826,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0304","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.2 Use of corticosteroids","content_type":"text","pages":"156","tokens_est":498,"char_count":1991,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0305","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.3 Treatment of MDR/RR-TB patients with HIV","content_type":"text","pages":"157","tokens_est":520,"char_count":2080,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0306","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV","content_type":"text","pages":"157","tokens_est":175,"char_count":698,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0307","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.1 Eligibility","content_type":"text","pages":"157","tokens_est":43,"char_count":170,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0308","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Co-administration of MDR-TB and HCV treatments","content_type":"text","pages":"158","tokens_est":730,"char_count":2919,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0309","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.2 Implementation considerations | Access to treatment for HCV and MDR-TB","content_type":"text","pages":"158","tokens_est":96,"char_count":382,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0310","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.3 Monitoring treatment response and outcome assignment","content_type":"text","pages":"159","tokens_est":259,"char_count":1036,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0311","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | 8.4.4 Monitoring safety","content_type":"text","pages":"159-160","tokens_est":652,"char_count":2605,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0312","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | Table 2.8.1. DDIs between MDR/RR-TB and HCV drugs","content_type":"table","pages":"160-161","caption":"Table 2.8.1. DDIs between MDR/RR-TB and HCV drugs","tokens_est":38,"char_count":637,"has_attachment":true,"attachment_id":"Table 2.8.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.8.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0313","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV","content_type":"text","pages":"161","tokens_est":159,"char_count":634,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0314","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV | Table 2.8.2. Characteristics of anti-TB drugs related to liver disease","content_type":"table","pages":"161-162","caption":"Table 2.8.2. Characteristics of anti-TB drugs related to liver disease","tokens_est":40,"char_count":159,"has_attachment":true,"attachment_id":"Table 2.8.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.8.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0315","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 8. Adjuncts to DR-TB treatment and comorbidities | 8.4 Treatment of MDR/RR-TB patients coinfected with HCV","content_type":"text","pages":"162","tokens_est":143,"char_count":569,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0316","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens","content_type":"text","pages":"164","tokens_est":72,"char_count":285,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0317","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.1 Policy and operational documents","content_type":"text","pages":"164","tokens_est":198,"char_count":792,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0318","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.2 National DR-TB expert committee or technical working group","content_type":"text","pages":"164","tokens_est":258,"char_count":1031,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0319","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.3 Electronic recording and reporting","content_type":"text","pages":"164-165","tokens_est":444,"char_count":1775,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0320","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.4 Estimates (epidemiological and logistics)","content_type":"text","pages":"165","tokens_est":449,"char_count":1794,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0321","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.5 Management of the supply chain and storage conditions for pharmaceuticals","content_type":"text","pages":"165-166","tokens_est":555,"char_count":2219,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0322","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens","content_type":"text","pages":"166-167","tokens_est":702,"char_count":2808,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0323","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | National level:","content_type":"text","pages":"167","tokens_est":236,"char_count":944,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0324","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Health facility level in adopting areas","content_type":"text","pages":"167","tokens_est":231,"char_count":922,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0325","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Table 2.9.1. List of activities and corresponding responsible organizations","content_type":"table","pages":"167-170","caption":"Table 2.9.1. List of activities and corresponding responsible organizations","tokens_est":31,"char_count":134,"has_attachment":true,"attachment_id":"Table 2.9.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.9.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0326","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Costing","content_type":"text","pages":"170","tokens_est":422,"char_count":1686,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0327","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.6 Preparation for the introduction of new treatment regimens | Monitoring and evaluation","content_type":"text","pages":"171","tokens_est":456,"char_count":1822,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0328","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety","content_type":"text","pages":"171","tokens_est":107,"char_count":428,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0329","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response","content_type":"text","pages":"171-172","tokens_est":601,"char_count":2403,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0330","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.1 Monitoring the treatment response | Treatment monitoring for special populations","content_type":"text","pages":"172","tokens_est":486,"char_count":1941,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0331","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | 9.7.2 Monitoring safety","content_type":"text","pages":"173","tokens_est":389,"char_count":1554,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0332","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.7 Monitoring treatment response and safety | Table 2.9.2. Recommended schedule of baseline, routine and post-treatment monitoring examinations for patients on DR-TB treatment [ a ]","content_type":"table","pages":"173-179","caption":"Table 2.9.2. Recommended schedule of baseline, routine and post-treatment monitoring examinations for patients on DR-TB treatment [ a ]","tokens_est":74,"char_count":1181,"has_attachment":true,"attachment_id":"Table 2.9.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.9.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0333","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.8 Treatment outcome definitions","content_type":"text","pages":"179","tokens_est":206,"char_count":824,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0334","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | 9.9 Post-treatment follow-up","content_type":"text","pages":"179-180","tokens_est":500,"char_count":1999,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0335","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 2 : Drug-resistant TB treatment | 9. Programmatic implementation of DR-TB regimens | Table 2.9.3. Post-end-of treatment schedule","content_type":"table","pages":"180","caption":"Table 2.9.3. Post-end-of treatment schedule","tokens_est":51,"char_count":211,"has_attachment":true,"attachment_id":"Table 2.9.3.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2.9.3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0336","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction","content_type":"text","pages":"198","tokens_est":465,"char_count":1858,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0337","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 1. Care and support interventions for all people with TB","content_type":"text","pages":"198","tokens_est":869,"char_count":3474,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0338","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 2. Models of care for people with drug-resistant TB","content_type":"text","pages":"198-199","tokens_est":112,"char_count":447,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0339","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 1. Introduction | Key WHO recommendations on TB care and support | 3. Models of care for children and adolescents exposed to TB or with TB disease","content_type":"text","pages":"199","tokens_est":149,"char_count":596,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0340","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"199-200","tokens_est":725,"char_count":2898,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0341","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"200-201","tokens_est":978,"char_count":3909,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0342","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 2. People- centred approach","content_type":"text","pages":"201","tokens_est":429,"char_count":1716,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0343","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"206","tokens_est":735,"char_count":2937,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0344","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence","content_type":"text","pages":"206-207","tokens_est":951,"char_count":3801,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0345","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"207-208","tokens_est":923,"char_count":3689,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0346","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management","content_type":"text","pages":"208-209","tokens_est":591,"char_count":2361,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0347","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.1 Informational and educational support","content_type":"text","pages":"209-210","tokens_est":912,"char_count":3647,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0348","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support","content_type":"text","pages":"210-211","tokens_est":583,"char_count":2331,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0349","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.2 Psychological and emotional support | Box: Support group","content_type":"box","pages":"211","caption":"Box: Support group","tokens_est":305,"char_count":1218,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0350","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.3 Material support","content_type":"text","pages":"211-212","tokens_est":840,"char_count":3357,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0351","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.1 Social support in TB management | 3.1.4 Companionship support","content_type":"text","pages":"212","tokens_est":390,"char_count":1559,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0352","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.1 Treatment support","content_type":"text","pages":"213","tokens_est":877,"char_count":3508,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0353","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"213-214","tokens_est":965,"char_count":3860,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0354","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"214-215","tokens_est":797,"char_count":3186,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0355","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.2 Treatment administration and digital adherence technologies | 3.2.2 Digital adherence technologies","content_type":"text","pages":"215-216","tokens_est":722,"char_count":2885,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0356","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"216-217","tokens_est":956,"char_count":3823,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0357","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 3. Care and support interventions to enable TB treatment adherence | 3.3 Selecting a suitable package of care and support for a patient","content_type":"text","pages":"217-218","tokens_est":350,"char_count":1398,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0358","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB","content_type":"text","pages":"220","tokens_est":694,"char_count":2776,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0359","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.1 Guiding principles for health education and counselling","content_type":"text","pages":"220-221","tokens_est":661,"char_count":2644,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0360","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling","content_type":"text","pages":"221","tokens_est":162,"char_count":648,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0361","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.1 Forming a therapeutic alliance","content_type":"text","pages":"221-222","tokens_est":639,"char_count":2555,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0362","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.2 Active listening","content_type":"text","pages":"222-223","tokens_est":493,"char_count":1970,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0363","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.3 Using non-verbal communication","content_type":"text","pages":"223","tokens_est":441,"char_count":1761,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0364","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.4 Asking questions","content_type":"text","pages":"223-226","tokens_est":397,"char_count":1586,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0365","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information","content_type":"text","pages":"226","tokens_est":389,"char_count":1553,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0366","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information | Table 1. Effective communication skills","content_type":"table","pages":"226","caption":"Table 1. Effective communication skills","tokens_est":131,"char_count":533,"has_attachment":true,"attachment_id":"Table 1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0368","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.2 Effective communication skills to provide health education and counselling | 4.2.5 Providing information","content_type":"text","pages":"226","tokens_est":8,"char_count":31,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0369","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"226-227","tokens_est":280,"char_count":1120,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0370","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | 1. Factual information about TB as a disease and its treatment","content_type":"text","pages":"227","tokens_est":256,"char_count":1023,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0371","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | 2. The rights of people affected by TB","content_type":"text","pages":"227","tokens_est":110,"char_count":437,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0372","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities | Table 2. The rights of people affected by TB and obligations of state and nonstate actors","content_type":"table","pages":"227-228","caption":"Table 2. The rights of people affected by TB and obligations of state and nonstate actors","tokens_est":33,"char_count":131,"has_attachment":true,"attachment_id":"Table 2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0373","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.3 Counselling to provide information about TB and the responsibilities of affected individuals and communities","content_type":"text","pages":"228-229","tokens_est":979,"char_count":3916,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0374","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment","content_type":"text","pages":"229","tokens_est":59,"char_count":236,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0375","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.1 Counselling to provide information about TB treatment","content_type":"text","pages":"230","tokens_est":142,"char_count":565,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0376","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.1 Counselling to provide information about TB treatment | Table 3. Information about TB treatment","content_type":"table","pages":"230","caption":"Table 3. Information about TB treatment","tokens_est":104,"char_count":416,"has_attachment":true,"attachment_id":"Table 3.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_3..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0377","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.1 Counselling to provide information about TB treatment","content_type":"text","pages":"230","tokens_est":45,"char_count":177,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0378","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment","content_type":"text","pages":"230","tokens_est":288,"char_count":1152,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0379","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 1. Home visit to engage with the patient","content_type":"text","pages":"230-231","tokens_est":144,"char_count":575,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0380","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 2. Assess the reasons for discontinuing treatment","content_type":"text","pages":"231","tokens_est":145,"char_count":578,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0381","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence","content_type":"text","pages":"231","tokens_est":56,"char_count":222,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0382","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | a. Manage side-effects","content_type":"text","pages":"231","tokens_est":81,"char_count":324,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0383","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | b. Explore the persons health beliefs","content_type":"text","pages":"231","tokens_est":258,"char_count":1032,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0384","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | c. Address economic problems","content_type":"text","pages":"232","tokens_est":68,"char_count":272,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0385","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | d. Address substance use or other mental health conditions","content_type":"text","pages":"232","tokens_est":94,"char_count":373,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0386","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | e. Problems with the health care service","content_type":"text","pages":"232","tokens_est":93,"char_count":371,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0387","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 3. Discuss the patients concerns that caused non-adherence | f. Address social problems","content_type":"text","pages":"232","tokens_est":87,"char_count":347,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0388","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 4. Educate the patient about need to continue treatment","content_type":"text","pages":"232","tokens_est":107,"char_count":427,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0389","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 5. Counsel and support the patient to resume treatment promptly","content_type":"text","pages":"232","tokens_est":124,"char_count":495,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0390","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.4 Counselling to provide information about TB treatment and to ensure adherence to treatment | 4.4.2 Counselling to ensure adherence to treatment | 6. Engage community health workers, family members and caregivers to ensure treatment adherence","content_type":"text","pages":"232-233","tokens_est":247,"char_count":987,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0391","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support","content_type":"text","pages":"233","tokens_est":152,"char_count":608,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0392","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | Table 4. Symptoms of stress","content_type":"table","pages":"233","caption":"Table 4. Symptoms of stress","tokens_est":26,"char_count":113,"has_attachment":true,"attachment_id":"Table 4.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_4..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0393","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support","content_type":"text","pages":"233-234","tokens_est":252,"char_count":1005,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0394","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.1 Basic psychological support","content_type":"text","pages":"234","tokens_est":619,"char_count":2474,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0395","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.2 Strengthen social support","content_type":"text","pages":"235","tokens_est":367,"char_count":1467,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0396","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.3 Problem-solving technique","content_type":"text","pages":"235-236","tokens_est":363,"char_count":1449,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0397","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.4 Provide support to the caregivers","content_type":"text","pages":"236","tokens_est":355,"char_count":1419,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0398","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.5 Counselling to provide psychological support | 4.5.5 Refer to mental health services","content_type":"text","pages":"236","tokens_est":38,"char_count":152,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0399","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support","content_type":"text","pages":"237","tokens_est":169,"char_count":674,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0400","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.1 Treat the underlying cause","content_type":"text","pages":"237","tokens_est":181,"char_count":724,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0401","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.2 Educate the person","content_type":"text","pages":"237-239","tokens_est":230,"char_count":917,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0402","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.4 Motivate the person","content_type":"text","pages":"239","tokens_est":178,"char_count":710,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0403","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.6 Counselling on nutritional care and support | 4.6.5 Rewarding desired behaviour (in children)","content_type":"text","pages":"239","tokens_est":68,"char_count":269,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0404","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.1 Counselling at the end of TB treatment and post-TB treatment","content_type":"text","pages":"239","tokens_est":346,"char_count":1381,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0405","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"240-241","tokens_est":976,"char_count":3903,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0406","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 4. Health education and counselling for people affected with TB | 4.7 Counselling at the end of TB treatment and on palliative care | 4.7.2 Counselling on palliative care","content_type":"text","pages":"241","tokens_est":280,"char_count":1120,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0407","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients","content_type":"text","pages":"245","tokens_est":407,"char_count":1626,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0408","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"245-246","tokens_est":823,"char_count":3289,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0409","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.1 Outpatient model of TB treatment: decentralized care","content_type":"text","pages":"246-247","tokens_est":796,"char_count":3184,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0410","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.2 Inpatient model of TB treatment and care","content_type":"text","pages":"247-248","tokens_est":851,"char_count":3402,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0411","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"248-249","tokens_est":958,"char_count":3829,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0412","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.1 Models of care for all TB patients | 5.1.3 Deciding on the best suited model for a situation","content_type":"text","pages":"249-250","tokens_est":453,"char_count":1810,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0413","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"250-251","tokens_est":937,"char_count":3746,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0414","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"251-252","tokens_est":938,"char_count":3752,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0415","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents","content_type":"text","pages":"252","tokens_est":725,"char_count":2897,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0416","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents | Treatment support","content_type":"text","pages":"252-253","tokens_est":280,"char_count":1117,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0417","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.2 Decentralized and integrated family- centred models of TB care for children and adolescents | Socioeconomic impact of TB on children, adolescents and families","content_type":"text","pages":"253","tokens_est":349,"char_count":1396,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0418","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.3 Models of service delivery for people with TB, HIV and comorbidities","content_type":"text","pages":"253-254","tokens_est":529,"char_count":2114,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0419","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.4 Private-sector involvement in TB care","content_type":"text","pages":"254","tokens_est":346,"char_count":1382,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0420","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 5. Models of care for TB services | 5.5 TB and health emergencies","content_type":"text","pages":"254","tokens_est":466,"char_count":1864,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0421","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care","content_type":"text","pages":"258","tokens_est":202,"char_count":805,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0422","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care?","content_type":"text","pages":"258","tokens_est":166,"char_count":661,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0423","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.1 Why is palliative care an essential part of comprehensive TB care?","content_type":"text","pages":"258","tokens_est":259,"char_count":1035,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0424","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.2 When and where should palliative care be provided for people with TB?","content_type":"text","pages":"258-259","tokens_est":554,"char_count":2214,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0425","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.3 Who should provide palliative care for people with TB?","content_type":"text","pages":"259","tokens_est":147,"char_count":586,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0426","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.1 What is palliative care? | 6.1.4 What is end-of-life care for people with TB?","content_type":"text","pages":"259","tokens_est":130,"char_count":518,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0427","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.1 Integration of palliative care into NTPs","content_type":"text","pages":"259-260","tokens_est":241,"char_count":963,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0428","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.1 Integration of palliative care into NTPs | Table 5. Palliative care interventions needed for people with TB","content_type":"table","pages":"260","caption":"Table 5. Palliative care interventions needed for people with TB","tokens_est":29,"char_count":125,"has_attachment":true,"attachment_id":"Table 5.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_5..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0429","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.2 Essential package of palliative care for people affected by TB","content_type":"text","pages":"260","tokens_est":255,"char_count":1019,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0430","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.2 Essential package of palliative care for people affected by TB | Table 6. Essential package of palliative care for people affected by TB (91, 105)","content_type":"table","pages":"261-262","caption":"Table 6. Essential package of palliative care for people affected by TB (91, 105)","tokens_est":30,"char_count":854,"has_attachment":true,"attachment_id":"Table 6.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_6..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0431","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.3 Oxygen for relief of mild dyspnoea","content_type":"text","pages":"262","tokens_est":70,"char_count":278,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0432","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.4 Morphine for safe relief of chronic or refractory dyspnoea","content_type":"text","pages":"262","tokens_est":267,"char_count":1066,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0433","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.5 Palliative care teamwork","content_type":"text","pages":"262","tokens_est":128,"char_count":512,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0434","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.6 Management of substance use disorders and other comorbidities","content_type":"text","pages":"263","tokens_est":345,"char_count":1377,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0435","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.7 M&E of palliative care for people affected by TB","content_type":"text","pages":"263","tokens_est":212,"char_count":848,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0436","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.2 Planning and implementing palliative care for people affected by TB | 6.2.8 Cost savings from palliative care integration into TB programmes","content_type":"text","pages":"263","tokens_est":182,"char_count":725,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0437","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.1 When should suspension of TB treatment be considered?","content_type":"text","pages":"263-264","tokens_est":205,"char_count":818,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0438","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.2 Important considerations in suspending TB treatment","content_type":"text","pages":"264","tokens_est":297,"char_count":1186,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0439","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"264-265","tokens_est":978,"char_count":3910,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0440","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.3 Decision-making about suspension of TB treatment","content_type":"text","pages":"265","tokens_est":115,"char_count":457,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0441","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Chapter 3 : Tuberculosis care and support | 6. Palliative care | 6.3 End-of-life care for people with TB | 6.3.4 Providing end-of-life care for people with TB","content_type":"text","pages":"265","tokens_est":329,"char_count":1313,"has_attachment":false,"source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0442","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Annex 4. Dosing of medicines used in TB regimens, adults and children | Table A4.1. Dosages of anti-TB medicines by weight band for treatment of DS-TB","content_type":"table","pages":"279","caption":"Table A4.1. Dosages of anti-TB medicines by weight band for treatment of DS-TB","tokens_est":57,"char_count":323,"has_attachment":true,"attachment_id":"Table A4.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_A4.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0443","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Annex 4. Dosing of medicines used in TB regimens, adults and children","content_type":"table","pages":"279-280","caption":"Table A4.1.1. Dosages of adult fixed-dose combinations","tokens_est":23,"char_count":189,"has_attachment":true,"attachment_id":"Table A4.1.1.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_A4.1.1..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
{"chunk_id":"WHO_TB_handbook_module4_treatment_2025|0444","doc_id":"WHO_TB_handbook_module4_treatment_2025","section_path":"Annex 4. Dosing of medicines used in TB regimens, adults and children | Table A4.2. Weight-based dosing of medicines used in multidrug-resistant TB regimens, adults and children [ a]","content_type":"table","pages":"282-310","caption":"Table A4.2. Weight-based dosing of medicines used in multidrug-resistant TB regimens, adults and children [ a]","tokens_est":85,"char_count":6656,"has_attachment":true,"attachment_id":"Table A4.2.","attachment_path":"tables/WHO_TB_handbook_module4_treatment_2025/Table_A4.2..csv","source_manifest":"..\\rag-chunker\\manifests\\WHO_TB_handbook_module4_treatment_2025_manifest.xlsx"}
